Form 4: Director Bruce Bodaken Receives RSU Grant at iRhythm

Director Bruce G. Bodaken was granted 1,573 restricted stock units in iRhythm Holdings, Inc. as part of standard equity compensation.

Summary

• Director Bruce G. Bodaken acquired 1,573 restricted stock units (RSUs) on May 27, 2026.
• Each RSU represents a contingent right to receive one share of iRhythm Holdings, Inc. (IRTC) common stock.
• The grant results in a total beneficial ownership of 14,211 shares held directly by the director.
• The RSUs vest on the earlier of one year from the grant date or the date of the next annual meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified; this is a routine equity grant disclosure.

Risks

• Standard market risks associated with equity ownership in the medical technology sector.

Future Outlook

The RSUs are scheduled to vest on the earlier of one year from the grant date or the date of the company's next annual meeting.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to incentivize long-term performance and align director interests with those of the shareholders.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for publicly traded medical technology companies.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 1,573 RSUs upon the earlier of one year or the next annual meeting.

Key Dates

Keywords

iRhythm, IRTC, Form 4, Insider Trading, Director Compensation, Equity Grant